Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent therapy in advanced melanoma (MEL)

被引：0
|
作者：
Sznol, Mario
Kluger, Harriet M.
Callahan, Margaret K.
Postow, Michael Andrew
Gordon, Ruth Ann
Segal, Neil Howard
Rizvi, Nalyer A.
Lesokhin, Alexander M.
Atkins, Michael B.
Kirkwood, John M.
Burke, Matthew M.
Ralabate, Amanda L.
Rivera, Angel L.
Kronenberg, Stephanie Anne
Agunwamba, Blessing
Feely, William
Hong, Quan
Krishnan, Suba
Gupta, Ashok Kumar
Wolchok, Jedd D.
机构：
[1] Yale Canc Ctr, New Haven, CT USA
[2] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
[3] Georgetown Lombardi Comprehens Canc Ctr, Washington, DC USA
[4] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA
[5] Bristol Myers Squibb Co, Princeton, NJ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LBA9003
引用
收藏
页数：1
相关论文
共 50 条
  • [11] Long-term survival of ipilimumab-naive patients (pts) with advanced melanoma (MEL) treated with nivolumab (anti-PD-1, BMS-936558, ONO-4538) in a phase I trial.
    Hodi, F. Stephen
    Sznol, Mario
    Kluger, Harriet M.
    McDermott, David F.
    Carvajal, Richard D.
    Lawrence, Donald P.
    Topalian, Suzanne Louise
    Atkins, Michael B.
    Powderly, John D.
    Sharfman, William Howard
    Puzanov, Igor
    Smith, David C.
    Leming, Philip D.
    Lipson, Evan J.
    Taube, Janis M.
    Anders, Robert
    Horak, Christine E.
    Kollia, Georgia
    Gupta, Ashok Kumar
    Sosman, Jeffrey Alan
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [12] An open-label, randomized, phase II study of nivolumab (anti-PD-1; BMS-936558; ONO-4538) given sequentially with ipilimumab in patients (pts) with advanced or metastatic melanoma (MEL).
    Hodi, F. Stephen
    Baudelet, Christine
    Chen, Allen C.
    Weber, Jeffrey S.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [13] Survival and long-term follow-up of safety and response in patients (pts) with advanced melanoma (MEL) in a phase I trial of nivolumab (anti-PD-1; BMS-936558; ONO-4538)
    Sznol, Mario
    Kluger, Harriet M.
    Hodi, F. Stephen
    McDermott, David F.
    Carvajal, Richard D.
    Lawrence, Donald P.
    Topalian, Suzanne Louise
    Atkins, Michael B.
    Powderly, John D.
    Sharfman, William Howard
    Puzanov, Igor
    Smith, David C.
    Wigginton, Jon M.
    Kollia, Georgia
    Gupta, Ashok Kumar
    Sosman, Jeffrey Alan
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [14] Nivolumab (anti-PD-1, BMS-936558, ONO-4538) in patients with advanced non-small cell lung cancer
    Rajan, Arun
    Gulley, James L.
    TRANSLATIONAL LUNG CANCER RESEARCH, 2014, 3 (06) : 403 - 405
  • [15] Survival and long-term follow-up of safety and response in patients (pts) with advanced melanoma (MEL) in a phase I trial of nivolumab (anti-PD-1; BMS-936558; ONO-4538).
    Sznol, Mario
    Kluger, Harriet M.
    Hodi, F. Stephen
    McDermott, David F.
    Carvajal, Richard D.
    Lawrence, Donald P.
    Topalian, Suzanne Louise
    Atkins, Michael B.
    Powderly, John D.
    Sharfman, William Howard
    Puzanov, Igor
    Smith, David C.
    Wigginton, Jon M.
    Kollia, Georgia
    Gupta, Ashok Kumar
    Sosman, Jeffrey Alan
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (18)
  • [16] Survival and long-term safety in patients (pts) with advanced solid tumors receiving nivolumab (anti-PD-1; BMS-936558; ONO-4538)
    Hodi, F. S.
    Topalian, S. L.
    Brahmer, J. R.
    McDermott, D. F.
    Smith, D. C.
    Gettinger, S.
    Taube, J. M.
    Pardoll, D. M.
    Wigginton, J. M.
    Sznol, M.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S185 - S185
  • [17] Nivolumab (anti-PD-1; BMS-936558, ONO-4538) and ipilimumab in first-line NSCLC: Interim phase I results.
    Antonia, Scott Joseph
    Gettinger, Scott N.
    Chow, Laura Quan Man
    Juergens, Rosalyn A.
    Borghaei, Hossein
    Shen, Yun
    Harbison, Christopher
    Chen, Allen C.
    Ready, Neal
    Rizvi, Naiyer A.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [18] LONG-TERM SURVIVAL OF IPILIMUMAB-NAIVE PATIENTS WITH ADVANCED MELANOMA (MEL) TREATED WITH NIVOLUMAB (ANTI-PROGRAMMED DEATH-1; ANTI-PD-1; BMS-936558; ONO-4538) IN A PHASE I TRIAL
    Hodi, Stephen
    Sznol, Mario
    Kluger, Harriet M.
    McDermott, David F.
    Carvajal, Richard D.
    Lawrence, Donald P.
    Topalian, Suzanne L.
    Atkins, Michael B.
    Powderly, John D.
    Sharfman, William H.
    Puzanov, Igor
    Smith, David C.
    Leming, Philip D.
    Lipson, Evan J.
    Taube, Janis M.
    Anders, Robert A.
    Horak, Christine E.
    Kollia, Georgia
    Gupta, Ashok
    Sosman, Jeffrey A.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2014, 10 : 177 - 177
  • [19] Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with sunitinib or pazopanib in patients with metastatic renal cell carcinoma (mRCC)
    Amin, A.
    Plimack, E. R.
    Infante, J. R.
    Ernstoff, M. S.
    Rini, B.
    Mcdermott, D. F.
    Knox, J.
    Pal, S. K.
    Voss, M. H.
    Sharma, P.
    Kollmannsberger, C.
    Heng, D. Y. C.
    Spratlin, J.
    Shen, Y.
    Kurland, J. F.
    Gagnier, P.
    Hammers, H.
    BJU INTERNATIONAL, 2014, 114 : 2 - 2
  • [20] NIVOLUMAB (ANTI-PD-1; BMS-936558, ONO-4538) IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC): SURVIVAL AND CLINICAL ACTIVITY BY SUBGROUP ANALYSIS
    Rizvi, Naiyer A.
    Gettinger, Scott N.
    Horn, Leora
    Gandhi, Leena
    Spigel, David R.
    Powderly, John D.
    Heist, Rebecca S.
    Carvajal, Richard D.
    Jackman, David M.
    Sequist, Lecia V.
    Smith, David C.
    Leming, Philip D.
    Topalian, Suzanne L.
    Hodi, F. Stephen
    Sznol, Mario
    Harbison, Christopher T.
    Kollia, Georgia D.
    Brahmer, Julie R.
    Antonia, Scott J.
    JOURNAL OF THORACIC ONCOLOGY, 2014, 9 (09) : S152 - S152
12345